Results 181 to 190 of about 154,391 (307)

Therapeutic Applications of Stimuli‐Based Release and Engineering of Extracellular Vesicles

Advanced NanoBiomed Research, EarlyView.
This review summarizes the effects of endogenous and exogenous stimuli, their effects on the natural release of extracellular vesicles, as well as their uptake and release. It also gives an overview of stimuli‐responsive EVs and their therapeutic applications. Extracellular vesicles (EVs), nano‐ to microsized lipid bilayer membrane‐bound particles, are
Gloria Kemunto, Kristen Dellinger
wiley   +1 more source

Plant Virus Immunotherapy for HPV‐Associated Oropharyngeal Squamous Cell Carcinoma

Advanced NanoBiomed Research, EarlyView.
Cowpea mosaic virus (CPMV) nanoparticles are safe and potent cancer immunotherapy candidates with strong immunomodulatory activity. CPMV activates innate immunity, which in turn drives adaptive immune responses and promotes durable, systemic antitumor effects.
Jessica Fernanda Affonso de Oliveira, Patrick Opdensteinen, Andrea Simms, Seongwon Jung, Giuliana P. Mognol, Hui Chen, Judith A. Varner, Nicole F. Steinmetz   +7 more
wiley   +1 more source

Tumor suppressor U19/EAF2 regulates thrombospondin-1 expression via p53

, 2010
Inactivation of U19/EAF2 has been shown previously to lead to tumorigenesis in multiple organs; however, the mechanism of U19/EAF2 tumor suppression remains unclear.
Wang, Z, Univ Pittsburgh, Sch Med, Inst Canc, Dept Urol, 5200 Ctr Ave,Suite G40, Pittsburgh, PA 15232 USA, Pascal, L. E., Xiao, W., Su, F., Wang, Z.   +4 more
core  

Native Mass Spectrometry Reveals Binding Modes of the Tumor Suppressor Protein p53 to Different DNA Response Elements. [PDF]

J Am Soc Mass Spectrom
Siefke E, Arlt C, Sinz A.
europepmc   +1 more source

Tumor suppressor protein p53 negatively regulates ischemia-induced angiogenesis and arteriogenesis. [PDF]

J Vasc Surg, 2018
Pfaff MJ, Mukhopadhyay S, Hoofnagle M, Chabasse C, Sarkar R.   +4 more
europepmc   +1 more source

Network Theory Analysis of Allosteric Drug-Rescue Mechanisms in the Tumor Suppressor Protein p53 Y220C Mutant. [PDF]

Int J Mol Sci
Cowan BS, Thayer KM.
europepmc   +1 more source

MDMX in Cancer: A Partner of p53 and a p53-Independent Effector

Biologics: Targets & Therapy
Wu Lin,1,* Yuxiang Yan,2,* Qingling Huang,1 Dali Zheng2 1Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, People’s Republic of China; 2Fujian Key Laboratory of Oral Diseases ...
Lin W, Yan Y, Huang Q, Zheng D
doaj  

Δ133p53α and Δ160p53α isoforms of the tumor suppressor protein p53 exert dominant-negative effect primarily by co-aggregation. [PDF]

Elife
Zhao L, Punga T, Sanyal S.
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

From anthelmintic to neuro‐oncology: A systematic review of mebendazole repurposing for brain tumour therapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mebendazole (MBZ), a benzimidazole anthelmintic with established clinical use, has emerged as a repurposing candidate for primary brain tumours due to its multimodal anticancer actions and central nervous system penetrance. This systematic review synthesizes preclinical and clinical evidence evaluating MBZ's efficacy, mechanisms of action ...
Ciara B. Blum, Milli McMenamin, Tessa Khoo, John M. Edwin, Prathibha Jose, Liam A. O’Callaghan   +5 more
wiley   +1 more source